Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
801-820 of 2,251 trials

Psoriatic Arthritis: Tapering Immunosuppressive Therapy

We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.

Psoriatic Arthritis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineRheumatology

Noncardiac Surgery: Noradrenaline Infusion Study

We are investigating if noradrenaline infusion is more effective than standard blood pressure management in preventing low blood pressure during noncardiac surgery. This study aims to improve patient safety and outcomes in the operating room.

Low Blood Pressure During Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOtolaryngology

Ovarian Cancer: Niraparib Rechallenge Study

We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.

Ovarian Cancer with Oligometastatic Progression1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: SALVOVAR Trial on Chemotherapy Regimens

We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.

Advanced Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Liver Transplant: Regulatory T Cell Therapy

We are studying a new treatment using regulatory T cells for liver transplant recipients to see if it is safe and allows them to stop taking tacrolimus. We also want to learn how it affects graft function and patients' quality of life.

Liver TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Meniscal Loss: Spongioflex® Allografts Study

We are investigating whether sterile allogeneic spongioflex® allografts can improve knee function in patients with incomplete meniscal loss. The study will also assess safety and patient satisfaction over several years.

Meniscus Tear>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and Traumatology

Advanced Solid Tumors: AZD0901 Treatment Study

We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.

Gastric CancerGastroesophageal Junction CancerPancreatic Ductal AdenocarcinomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncologyUrology

Treatment-Resistant Depression: P-glycoprotein Study

We are investigating how a protein may affect people with treatment-resistant depression using advanced imaging. This study compares P-glycoprotein activity in those who do not respond to treatment with those who do.

Depression1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Liver Tumors: Indocyanine Green for Better Detection

We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.

Resectable Malignant Liver Tumor>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Relapsed/Refractory T-Cell Leukemia: CD7 CAR T-Cell Therapy

We are testing a new type of T-cell therapy for children and young adults with relapsed or refractory T-cell leukemia or lymphoma. The study aims to find a safe dose and see how well it works.

T-cell Acute Lymphoblastic Leukemia/Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Metastatic Pancreatic Adenocarcinoma: TTX-030 and Chemotherapy

We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Inflammatory Bowel Disease: Adalimumab-680LT Study

We are investigating the safety and imaging of a new version of adalimumab for people with inflammatory bowel diseases. This study aims to see how well the drug targets inflammation and its potential effects on health.

Inflammatory Bowel Disease (IBD)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Whooping Cough Vaccine: Tdap-IPV Study

We are studying whether a booster shot of the Tdap-IPV vaccine helps prevent colonization by whooping cough bacteria in healthy adults after exposure. This research aims to improve vaccination strategies against whooping cough.

Whooping Cough≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Head and Neck Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This trial looks at its use alone and with other standard treatments to see how well it works.

Recurrent Head and Neck CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

B-cell Acute Lymphoblastic Leukemia: CD19-CAR T Cell Therapy

We are testing a new type of CAR T cell therapy for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The study aims to evaluate the safety and appropriate dosage of this treatment.

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Chronic Lymphocytic Leukemia: Acalabrutinib vs. Venetoclax

We are comparing two treatment combinations for newly diagnosed chronic lymphocytic leukemia patients to see which is more effective and safer. We will also look at how these treatments affect patients' quality of life.

Chronic Lymphocytic Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology